One-Two Punch For Amgen: EMEA Rejects Vectibix, Recommends Approval For Roche's Mircera
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen says it intends to request a re-examination of panitumumab for the treatment of colorectal cancer in the EU.
You may also be interested in...
EMEA Recommends Conditional European Marketing Authorization For Amgen's Vectibix
Company requested a re-examination of its application for colorectal cancer after EMEA refused marketing approval in May.
EMEA Recommends Conditional European Marketing Authorization For Amgen's Vectibix
Company requested a re-examination of its application for colorectal cancer after EMEA refused marketing approval in May.
FDA Deems Mircera “Approvable” For Anemia Pending Cardio-Renal Committee Outcome
No further clinical trials involving the long-acting erythropoiesis-stimulating agent are anticipated, Roche says.